(TNGX) Tango Therapeutics - Ratings and Ratios

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a clinical-stage biotechnology company focused on developing precision cancer therapies. Its pipeline leverages synthetic lethality and other targeted approaches to address genetically defined cancers. The lead program, TNG908, is a small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) designed for cancers with methylthioadenosine phosphorylase (MTAP) deletions. TNG462, another MTAP-deletion targeting agent, is an oral methylthioadenosine (MTA)-cooperative inhibitor. The pipeline also includes TNG260, a repressor element-1 silencing transcription (REST) co-repressor inhibitor; TNG348, a ubiquitin-specific protease 1 (USP1) inhibitor for BRCA1/BRCA2-mutant cancers; and an undisclosed Target 3 for STK11-mutant cancers. Tango has a strategic collaboration with Gilead Sciences for cancer therapy development. Founded in 2017 and headquartered in Boston, Massachusetts, the company is advancing a portfolio of targeted oncology programs.

From a technical perspective, TNGX is currently trading below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The stocks average trading volume over the past 20 days is 691,325 shares, with a last price of $2.07. The ATR of 0.22 suggests moderate volatility. Resistance levels are at 9.9, 8.3, 7.3, 4.5, and 3.4. On the fundamental side, the company has a market cap of $252.43 million, a price-to-book ratio of 1.10, and a price-to-sales ratio of 5.82. The return on equity is -53.84, reflecting significant R&D investments without current profitability.

3-Month Forecast: Based on the technical and fundamental data, TNGX is expected to remain under pressure in the near term, with potential resistance at 3.4 and 4.5. The stocks position below its 20-day and 50-day moving averages suggests continued bearish momentum. However, the companys focused pipeline and collaboration with Gilead could provide upside catalysts if clinical data or partnership developments materialize. Investors should monitor progress in the PRMT5 and USP1 inhibitor programs, as well as any updates on the STK11-targeted candidate.